Oncogenic KRAS mutations lock the protein in its active state, resulting in persistent activation of downstream signaling cascades, such as the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways, which drive tumor growth and progression [13–16]. The gene discussed is KRAS; the disease is neoplasm.